Valencell Secures $8.4M in Funding to Advance High-Precision Biometric Sensing Technology

Valencell, a heart rate sensor company based in North Carolina, USA, recently secured $8.4 million in a new round of financing led by GII Tech, with participation from TDF Ventures and WSJ Joshua Fund. The total size of this funding round is $11 million. Last September, the company disclosed the initial tranche of this round in a filing with the U.S. Securities and Exchange Commission. To date, Valencell’s cumulative fundraising has reached $24.5 million.

Michael Dering, CEO of Valencell, revealed that the funding will be used to expand the company’s team and scale up its research and development efforts.

Founded in 2006, the company does not sell products directly to consumers; instead, it licenses its PerformTek heart rate sensing technology to various wearable device manufacturers. By wearing devices equipped with PerformTek sensing technology, users can measure their heart rate with high accuracy and great convenience. Currently, 25 companies have obtained licenses for PerformTek sensing technology, including Sony, Jabra, LG, iRiver, and Atlas Wearables. The two most recently announced licensees are BioConnected, which is developing high-resolution earphones, and Caeden, a company focused on fashionable health wearables.



Ryan Kraudel, Marketing Director at Valencell, stated, “The company’s current focus is on the healthcare and fitness sectors, while we also aim to delve deeper into the field of personal health management. We believe that in the future, the precision of exercise and fitness tracking will become central to the personal health management market, with applications extending further into emergency medical care and military sectors.”

Furthermore, Valencel has demonstrated strategic foresight by identifying broader commercial prospects through its service offerings to traditional medical device companies.

“After engaging with many traditional medical device companies, we found that although they are well aware of the broad market prospects for high-precision measurement devices, they lack the know-how to develop a product that people would willingly wear on a continuous basis,” explained Kraudel. “Even when some companies have managed to do so, the products they developed failed to meet the accuracy standards required for personal medical devices. Therefore, by addressing both aspects, an ideal product can be created.”

Compiled by Wang Jinfan